cancer and adenoma.[32,33] Depletion of 5,10-methylene-tetrahydrofolate results in uracil misincorporation into DNA, and removal of this abnormal base may lead to single- and double-strand breaks.[34]

Cigarette smoking is another important environmental risk factor in colorectal cancer.[35] In this dataset, there was no association between cigarette smoking and colorectal cancer risk.[36] In addition, we found no interaction between cigarette smoking and *XRCC1* polymorphisms in the risk of colorectal cancer (data not shown).

Several methodological strengths of the present study warrant mention. First, this is the largest published study to examine the association between *XRCC1* polymorphisms and colorectal cancer in Japan. Among previous large studies, 1 study in the United States included 1604 patients with colon cancer and 1969 control subjects.[11] Another in Taiwan investigated 727 case and 736 controls.[17] Sample size is particularly important in investigating the role of rare genotypes in gene-environment or gene-gene interactions. Second, our study used community controls and an ethnically homogeneous population. Third, although we used alcohol consumption 5 years before the referent date, recall of this information was found to be highly reproducible and valid.[37]

The methodological weaknesses of the study were as follows. First, participation in genotyping was not particularly high for either cases (65%) or controls (56%). However, the frequency of the *XRCC1* 399Gln allele (25%) was similar to that reported in other Japanese populations,[13,38] and the frequency of the *XRCC1* 194Trp allele (32%) was consistent with the results of a study in Japanese (30%).[39] Information on the frequency of the *XRCC1* 280His allele in a Japanese population was not available because, to our knowledge, the present study is the first to report an association between the *XRCC1* Arg280His polymorphism and cancer risk in Japan. However, the frequency of the *XRCC1* 280His allele (9%) in our study was similar to that in Asian/Pacific islanders (9%).[40] Second, because the community controls were not strictly investigated for the absence of colorectal cancer, such as by colonoscopy, we cannot exclude the possibility of misclassification of disease status. In addition, there are other DNA repair pathways (eg, base-excision repair, nucleotide-excision repair, mismatch repair, homologous recombination, and non-homologous end-joining), which are associated with many genetic polymorphisms, such as *OGG1*, *XPD*, *XPC*, *MSH6*, *XRCC3*, and *XRCC4*. However, we analyzed only *XRCC1* polymorphisms in this study. It is necessary to examine associations between other polymorphisms of DNA repair gene and colorectal cancer risk in the future.

In conclusion, the findings add evidence to the hypothesis that individuals with the *XRCC1* 399Gln/Gln genotype are at increased risk of colorectal cancer and that *XRCC1* polymorphisms have an important role in colorectal cancer risk related to alcohol consumption or gene-gene interaction.

ACKNOWLEDGMENTS

This work was supported by a Grant-in-Aid for Young Scientists (B) from the Ministry of Education, Culture, Sports, Science and Technology, Japan (21790584). The authors thank Professor Suminori Kono (principal investigator of the Fukuoka Colorectal Cancer Study), Kyushu University. The authors acknowledge the support of Emeritus Professor Keizo Sugimachi; Professors Seiyo Ikeda, Takayuki Shirakusa, and Sumitaka Arima; and Drs. Motonori Saku, Yoichi Ikeda, Soichiro Maekawa, Kazuo Tanoue, Kinjiro Sumiyoshi, and Shoichiro Saito in conducting the survey of cases. The authors thank Drs. Hideaki Baba, Tomonori Endo, Hiroshi Hara, Yoichiro Hirokata, Motohisa Ikeda, Masayoshi Ishibashi, Fumiaki Itoh, Yasuhiro Iwanaga, Hideki Kaku, Shoshi Kaku, Minoru Kanazawa, Akira Kobayashi, Ryunosuke Kumashiro, Shinichi Matsumoto, Soukei Mioka, Umeji Miyakoda, Osamu Nakagaki, Nobuyoshi Nogawa (deceased), Nobuyuki Ogami, Toyoaki Okabayashi, Hironao Okabe, Nishiki Saku, Masafumi Tanaka, Masahiro Ueda, Bunichi Ushio, and Koheisho Yasunaga for kindly supervising the surveys of the controls at their clinics.

Conflicts of interest: None declared.

REFERENCES

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.
2. Yiu HY, Whittemore AS, Shibata A. Increasing colorectal cancer incidence rates in Japan. Int J Cancer. 2004;109:777–81.
3. Mohrenweiser HW, Carrano AV, Fertitta A, Perry B, Thompson LH, Tucker JD, et al. Refined mapping of the three DNA repair genes, ERCC1, ERCC2, and XRCC1, on human chromosome 19. Cytogenet Cell Genet. 1989;52:11–4.
4. Shen MR, Jones IM, Mohrenweiser H. Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res. 1998; 58:604–8.
5. Lunn RM, Langlois RG, Hsieh LL, Thompson CL, Bell DA. XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency. Cancer Res. 1999; 59:2557–61.
6. Hsieh LL, Chien HT, Chen IH, Liao CT, Wang HM, Jung SM, et al. The XRCC1 399Gln polymorphism and the frequency of p53 mutations in Taiwanese oral squamous cell carcinomas. Cancer Epidemiol Biomarkers Prev. 2003;12:439–43.
7. Beckman KB, Ames BN. Oxidative decay of DNA. J Biol Chem. 1997;272:19633–6.
8. Ladiges W, Wiley J, MacAuley A. Polymorphisms in the DNA repair gene XRCC1 and age-related disease. Mech Ageing Dev. 2003;124:27–32.
9. Abdel-Rahman SZ, Soliman AS, Bondy ML, Omar S, El-Badawy SA, Khaled HM, et al. Inheritance of the 194Trp and the 399Gln variant alleles of the DNA repair gene XRCC1 are associated with increased risk of early-onset colorectal carcinoma in Egypt. Cancer Lett. 2000;159:79–86.

10. Hong YC, Lee KH, Kim WC, Choi SK, Woo ZH, Shin SK, et al. Polymorphisms of XRCC1 gene, alcohol consumption and colorectal cancer. Int J Cancer. 2005;116:428–32.
11. Curtin K, Samowitz WS, Wolff RK, Ulrich CM, Caan BJ, Potter JD, et al. Assessing tumor mutations to gain insight into base excision repair sequence polymorphisms and smoking in colon cancer. Cancer Epidemiol Biomarkers Prev. 2009;18:3384–8.
12. Improta G, Sgambato A, Bianchino G, Zupa A, Grieco V, La Torre G, et al. Polymorphisms of the DNA repair genes XRCC1 and XRCC3 and risk of lung and colorectal cancer: a case-control study in a Southern Italian population. Anticancer Res. 2008;28:2941–6.
13. Kasahara M, Osawa K, Yoshida K, Miyaishi A, Osawa Y, Inoue N, et al. Association of MUTYH Gln324His and APEX1 Asp148Glu with colorectal cancer and smoking in a Japanese population. J Exp Clin Cancer Res. 2008;27:49.
14. Moreno V, Gemignani F, Landi S, Gioia-Patricola L, Chabrier A, Blanco I, et al. Polymorphisms in genes of nucleotide and base excision repair: risk and prognosis of colorectal cancer. Clin Cancer Res. 2006;12:2101–8.
15. Skjelbred CF, Saebø M, Wallin H, Nexø BA, Hagen PC, Lothe IM, et al. Polymorphisms of the XRCC1, XRCC3 and XPD genes and risk of colorectal adenoma and carcinoma, in a Norwegian cohort: a case control study. BMC Cancer. 2006; 6:67.
16. Stern MC, Conti DV, Siegmund KD, Corral R, Yuan JM, Koh WP, et al. DNA repair single-nucleotide polymorphisms in colorectal cancer and their role as modifiers of the effect of cigarette smoking and alcohol in the Singapore Chinese Health Study. Cancer Epidemiol Biomarkers Prev. 2007;16:2363–72.
17. Yeh CC, Sung FC, Tang R, Chang-Chieh CR, Hsieh LL. Polymorphisms of the XRCC1, XRCC3, & XPD genes, and colorectal cancer risk: a case-control study in Taiwan. BMC Cancer. 2005;5:12.
18. Berndt SI, Huang WY, Fallin MD, Helzlsouer KJ, Platz EA, Weissfeld JL, et al. Genetic variation in base excision repair genes and the prevalence of advanced colorectal adenoma. Cancer Res. 2007;67:1395–404.
19. WCRF/AICR, Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective 2nd ed. Washington DC: American Institute for Cancer Research; 2007.
20. Mizoue T, Inoue M, Wakai K, Nagata C, Shimazu T, Tsuji I, et al. Alcohol drinking and colorectal cancer in Japanese: a pooled analysis of results from five cohort studies. Am J Epidemiol. 2008;167:1397–406.
21. Yin G, Kono S, Toyomura K, Moore MA, Nagano J, Mizoue T, et al. Alcohol dehydrogenase and aldehyde dehydrogenase polymorphisms and colorectal cancer: the Fukuoka Colorectal Cancer Study. Cancer Sci. 2007;98:1248–53.
22. Rossit AR, Cabral IR, Hackel C, da Silva R, Froes ND, Abdel-Rahman SZ. Polymorphisms in the DNA repair gene XRCC1 and susceptibility to alcoholic liver cirrhosis in older Southeastern Brazilians. Cancer Lett. 2002;180:173–82.
23. Kono S, Toyomura K, Yin G, Nagano J, Mizoue T. A case-control study of colorectal cancer in relation to lifestyle factors and genetic polymorphisms: design and conduct of the Fukuoka colorectal cancer study. Asian Pac J Cancer Prev. 2004; 5:393–400.
24. Isomura K, Kono S, Moore MA, Toyomura K, Nagano J, Mizoue T, et al. Physical activity and colorectal cancer: the Fukuoka Colorectal Cancer Study. Cancer Sci. 2006; 97:1099–104.
25. Yin J, Vogel U, Ma Y, Qi R, Sun Z, Wang H. The DNA repair gene XRCC1 and genetic susceptibility of lung cancer in a northeastern Chinese population. Lung Cancer. 2007;56:153–60.
26. Brooks PJ. DNA damage, DNA repair, and alcohol toxicity—a review. Alcohol Clin Exp Res. 1997;21:1073–82.
27. Hoek JB, Pastorino JG. Ethanol, oxidative stress, and cytokine-induced liver cell injury. Alcohol. 2002;27:63–8.
28. Brooks PJ, Theruvathu JA. DNA adducts from acetaldehyde: implications for alcohol-related carcinogenesis. Alcohol. 2005; 35:187–93.
29. Singletary KW, Barnes SL, van Breemen RB. Ethanol inhibits benzo[a]pyrene-DNA adduct removal and increases 8-oxo-deoxyguanosine formation in human mammary epithelial cells. Cancer Lett. 2004;203:139–44.
30. Błasiak J. Ethanol and acetaldehyde impair the repair of bleomycin-damaged DNA in human lymphocytes. Cytobios. 2001;106 Suppl 2:141–9.
31. Mason JB, Choi SW. Effects of alcohol on folate metabolism: implications for carcinogenesis. Alcohol. 2005;35:235–41.
32. Giovannucci E. Epidemiologic studies of folate and colorectal neoplasia: a review. J Nutr. 2002;132(8 Suppl):2350S–5S.
33. Kono S, Chen K. Genetic polymorphisms of methylene-tetrahydrofolate reductase and colorectal cancer and adenoma. Cancer Sci. 2005;96:535–42.
34. Blount BC, Mack MM, Wehr CM, MacGregor JT, Hiatt RA, Wang G, et al. Folate deficiency causes uracil misincorporation into human DNA and chromosome breakage: implications for cancer and neuronal damage. Proc Natl Acad Sci USA. 1997;94:3290–5.
35. Liang PS, Chen TY, Giovannucci E. Cigarette smoking and colorectal cancer incidence and mortality: systematic review and meta-analysis. Int J Cancer. 2009;124:2406–15.
36. Nisa H, Kono S, Yin G, Toyomura K, Nagano J, Mibu R, et al. Cigarette smoking, genetic polymorphisms and colorectal cancer risk: the Fukuoka Colorectal Cancer Study. BMC Cancer. 2010; 10:274.
37. Uchida K, Kimura Y, Shirota T, Kono S. Validity and reproducibility of the PC-assisted dietary interview used in the Fukuoka Colorectal Cancer Study. Asian Pac J Cancer Prev. 2007;8:583–90.
38. Ito H, Matsuo K, Hamajima N, Mitsudomi T, Sugiura T, Saito T, et al. Gene-environment interactions between the smoking habit and polymorphisms in the DNA repair genes, APE1 Asp148Glu and XRCC1 Arg399Gln, in Japanese lung cancer risk. Carcinogenesis. 2004;25:1395–401.
39. Hirata H, Hinoda Y, Tanaka Y, Okayama N, Suehiro Y, Kawamoto K, et al. Polymorphisms of DNA repair genes are risk factors for prostate cancer. Eur J Cancer. 2007;43:231–7.
40. Stern MC, Siegmund KD, Corral R, Haile RW. XRCC1 and XRCC3 polymorphisms and their role as effect modifiers of unsaturated fatty acids and antioxidant intake on colorectal adenomas risk. Cancer Epidemiol Biomarkers Prev. 2005; 14:609–15.

Clinical Study

Oncology

Oncology 2013;84:233–239
DOI: 10.1159/000346690

Received: November 1, 2012
Accepted after revision: December 17, 2012
Published online: January 31, 2013

Phase II Trial of Alternating mFOLFOX6 and FOLFIRI Regimens in the First-Line Treatment for Unresectable or Metastatic Colorectal Cancer (KSCC0701)

Eiji Oki[b] Yasunori Emi[b] Yoshito Akagi[a] Shoji Tokunaga[c] Noriaki Sadanaga[d] Takaho Tanaka[e] Yutaka Ogata[a] Hiroshi Saeki[b] Yoshihiro Kakeji[f] Hideo Baba[g] Tadashi Nishimaki[h] Shoji Natsugoe[i] Kazuo Shirouzu[a] Yoshihiko Maehara[b] Kyushu Study Group of Clinical Cancer

[a]Department of Surgery, Kurume University School of Medicine, Kurume, [b]Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, [c]Medical Information Center, Kyushu University Hospital, [d]Department of Surgery, Saiseikai Fukuoka General Hospital, and [e]Department of Surgery, Social Insurance Tagawa Hospital, Fukuoka, [f]Division of Gastrointestinal Surgery, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, [g]Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, [h]Division of Digestive and General Surgery, University of the Ryukyus Faculty of Medicine, Okinawa, and [i]Department of Surgical Oncology and Digestive Surgery, Kagoshima University, Kagoshima, Japan

Key Words
Colorectal cancer · Oxaliplatin · Irinotecan · FOLFOX6 · FOLFIRI · FIREFOX · Neurotoxicity

Abstract
Objective: This phase II study examined the efficacy and safety of alternating regimens of mFOLFOX6 and FOLFIRI as a first-line treatment for unresectable or metastatic colorectal cancer. ***Patients and Methods:*** Forty-eight patients were enrolled in this study. Patients received an alternating regimen of 4 cycles of mFOLFOX6 followed by 4 cycles of FOLFIRI. ***Results:*** The characteristics of the study population were as follows: males/females 34/12, median age 66 years (range 43–75) and Eastern Cooperative Oncology Group performance status 0/1/2 in 37/9/0 patients. The overall response rate was 58.7% [95% confidence interval (CI) 43.9–73.5]. The median progression-free survival was 10.3 months (95% CI 7.5–11.9), and the median overall survival was 28.4 months (95% CI 22.5–35.7). Among the 47 patients evaluated for toxicity, the most common grade 3–4 adverse events were leukopenia (26%), neutropenia (55%), anemia (4%), neurotoxicity (0%), diarrhea (2%), febrile neutropenia (4%), nausea (4%), vomiting (2%), and hypersensitivity (0%). ***Conclusions:*** The results of this phase II study indicate that this alternating schedule is effective and well tolerated as a first-line treatment for unresectable or metastatic colorectal cancer. The low rate of grade 3 neurotoxicity is also promising.

Introduction

Colorectal cancer is the second most common form of cancer in Western countries. The development of metastatic disease is the leading cause of death from colon can-

KARGER
E-Mail karger@karger.com
www.karger.com/ocl

0030–2414/13/0844–0233$38.00/0

Eiji Oki
Department of Surgery and Science, Graduate School of Medical Sciences
Kyushu University
Maidashi 3-1-1, Higashi-ku, Fukuoka 812-8582 (Japan)
E-Mail okieiji@surg2.med.kyushu-u.ac.jp

cer. Over the past decade, the results of clinical studies in patients with metastatic colorectal cancer have revealed substantial improvements in survival [1, 2]. 5-Fluorouracil (5-FU)-based chemotherapy is the mainstay of treatment for patients with metastatic colorectal cancer. Combinations of infusional 5-FU, leucovorin and oxaliplatin (FOLFOX) and infusional 5-FU, leucovorin and irinotecan (FOLFIRI), with or without molecular targeting agents, are considered standard treatments for metastatic colorectal cancer [1–5]. The order of combinations for first- and second-line treatment, for example FOLFOX followed by FOLFIRI or FOLFIRI followed by FOLFOX, does not affect patient survival [1]. However, 20–30% of patients do not proceed to second-line treatment [6]. Therefore, adequate and active first-line treatment is essential in the treatment of colorectal cancer. As exposure to active agents, i.e. 5-FU, oxaliplatin and irinotecan, rather than second-line therapy itself appears to predict improved survival [7], the 'up-front' administration of these 3 effective drugs may be the most effective means of improving outcomes. Consequently, several groups have investigated the triple-drug FOLFOXIRI regimen (5-FU, oxaliplatin and irinotecan) in patients with metastatic colorectal cancer to improve their prognosis [8, 9]. FOLFOXIRI resulted in significant increases in activity, efficacy and improvements in the long-term outcome. However, the triple-drug regimen causes further adverse effects [10, 11]. In particular, neurotoxicity is a common and frequent adverse event that diminishes the dose that can be administered [8, 12]. We hypothesized that alternating oxaliplatin and irinotecan would allow patients to benefit from concurrent treatment with all 3 drugs as soon as they were diagnosed with metastatic disease while allowing them to recover from the adverse events associated with each drug before its administration was repeated. The aim of this study was to explore the efficacy and safety of alternating regimens of 4 cycles of mFOLFOX6 and 4 cycles of FOLFIRI (FIREFOX) in the first-line treatment of advanced colorectal cancer. Specifically, we wanted to evaluate the impact of this schedule on the dose-limiting neurotoxicity and diarrhea associated with oxaliplatin and irinotecan.

Methods

Eligibility Criteria

Patients with histologically proven, unresectable, advanced or metastatic colorectal cancer who had not received any previous treatment were eligible for the study if they met all of the following criteria: measurable disease, age ≥20 and ≤75 years, Eastern Cooperative Oncology Group performance status ≤2, life expectancy ≥3 months and adequate bone marrow, hepatic and renal function. Written informed consent was obtained from all patients prior to enrollment in the study. The ethical, medical and scientific aspects of the study were reviewed and approved by the ethics committees of each participating institution in the University Hospital Medical Information Network clinical trials registry (UMIN000001340). The study was conducted in accordance with the Declaration of Helsinki of 1975, revised in 2000.

Treatment Schedule

Patients received an alternating regimen of 4 cycles of mFOLFOX-6 (85 mg/m^2 oxaliplatin, 200 mg/m^2 leucovorin on day 1 followed by 400 mg/m^2 bolus 5-FU and a 46-hour 2,400-mg/m^2 5-FU infusion every 2 weeks) followed by 4 cycles of FOLFIRI (oxaliplatin replaced with 150 mg/m^2 irinotecan on day 1). This schedule was repeated until unacceptable toxicity or progressive disease (PD) was observed. Treatment was administered until the observation of PD or unacceptable toxicity, withdrawal of consent, the physician's decision to terminate, or interruption of treatment for >14 days occurred. Dose modification was performed based on the hematological parameters and the degree of non-hematological toxicities. Chemotherapy was delayed until recovery if neutrophil counts decreased to <1,500/mm^3, platelet counts decreased to <75,000/mm^3, or significant persistent non-hematological toxicity occurred. The 5-FU dose was reduced to 300 (bolus) or 500 mg/m^2 (infusion) if grade 3/4 diarrhea, stomatitis, nausea/vomiting, anorexia, dermatitis, grade 4 neutropenia, or grade 3/4 thrombocytopenia occurred. Oxaliplatin was also reduced to 65 mg/m^2 for the same conditions, except for the occurrence of dermatitis; additionally, it was reduced in cases of persistent (15 days or longer) grade 2 neurotoxicity or temporary (8–14 days) grade 3 neurotoxicity. In cases of persistent (15 days or longer) grade 3 neurotoxicity or temporary grade 4 neurotoxicity, oxaliplatin was omitted from the regimen. The irinotecan dose was reduced to 130 mg/m^2 for the same reasons as described for oxaliplatin. The use of Ca/Mg treatment was not regulated as part of this protocol.

Endpoints

The primary endpoint of the study was the response rate (RR), and the secondary endpoints were progression-free survival (PFS), overall survival (OS) and adverse effects. During the 4 weeks before chemotherapy was initiated, all patients underwent the following: physical examination, complete blood cell count, hepatic and renal function tests, and chest and abdominal computed tomography or magnetic resonance imaging. A physical examination, hepatorenal function tests and blood counts were performed before each cycle. Patients were assessed before starting each 2-week cycle according to the National Cancer Institute Common Toxicity Criteria version 3 [13]. Tumor evaluation was performed every month for the first 3 months and then every 2 months thereafter using the Response Evaluation Criteria in Solid Tumors version 1.0 [14]. A complete response (CR) was defined as the disappearance of all known lesions and the absence of new lesions. A partial response (PR) was defined as a reduction of 30% or more in the sum of the maximum tumor lengths of up to 10 known lesions and the absence of new lesions. Stable disease (SD) was defined as a reduction of <30% or an increase of <20% in the sum of the maximum tumor lengths of up to 10 known lesions and the absence of new lesions.

PD was defined as an increase of ≥20% in the sum of the maximum tumor lengths of up to 10 known lesions or as the appearance of at least 1 new lesion.

Statistical Considerations

Using the binomial exact method (DSTPLAN) with a null RR of 40%, an expected RR of 60%, one-sided $\alpha = 0.05$ and power of 80%, 42 patients were needed for the study. Allowing that 10% of patients would be ineligible or drop out, the planned target number of patients was 47. The confidence interval (CI) for the RR was estimated by the exact method. The duration of survival was measured from the day of entry into the study, and the OS and PFS curves were calculated by the Kaplan-Meier method. A one-sided $p < 0.05$ was considered statistically significant at the statistical test of the primary endpoint. All statistical analyses were performed using Stata version 11 statistical analysis software (Stata, College Station, Tex., USA).

Results

Patient Characteristics

Between July 2007 and June 2008, 48 patients in 25 institutions in Japan were enrolled in this trial. Two of the patients did not meet the eligibility criteria: 1 did not undergo a prior imaging examination and the other had multiple active cancers. Forty-seven patients were treated with protocol therapy. Response, OS and PFS were assessed in 46 patients. The characteristics of 47 patients and those eligible for study inclusion are listed in table 1. The median number of administration cycles was 12 (range 1–47). Toxicity and tolerability were assessed with all 47 patients who received protocol therapy.

Efficacy

The overall RR as determined by the independent committee was 58.7% (95% CI 43.5–73.5), and it included 1 CR (2.1%) and 26 PRs (56.5%). The number of instances of SD and PD were 14 (30.4%) and 2 (4.3%), respectively; 3 (6.5%) patients were not evaluable (table 2). The tumor control rate (CR + PR + SD) was 89.1%. Irrespective of the order of treatment, the period from registration to the first evidence of progression on imaging analysis was defined as PFS. After a median follow-up of 27.5 months, the median PFS was 10.3 months in the 46 assessable patients (95% CI 7.5–11.9; fig. 1), and the median OS was 28.4 months in those patients (95% CI 22.5–35.7; fig. 2). The 1-, 2- and 3-year survival rates were 84.5% (95% CI 70.5–92.4), 60.2% (95% CI 44.4–72.7) and 32.9% (95% CI 17.8–48.8), respectively. Surgery was performed in 9 patients (19.6%) after treatment.

Table 1. Baseline patient characteristics

Characteristic	All cases (n = 47)
Age, years	
Median	66
Range	43–75
Gender	
Male	35 (74.5)
Female	12 (25.5)
Performance status	
0	38 (80.9)
1	9 (19.1)
Existence of a primary tumor	
Yes	19 (40.4)
No	28 (59.6)
Site of the primary tumor	
C	1 (5.3)
A	3 (15.8)
T	3 (15.8)
D	1 (5.3)
S	5 (26.3)
RS	1 (5.3)
Ra	2 (10.5)
Rb	3 (15.8)

Figures in parentheses are percentages. C = Cecum; A = ascending colon; T = transverse colon; D = descending colon; S = sigmoid colon; RS = rectosigmoid colon; Ra = rectum above the peritoneal reflection; Rb = rectum below the peritoneal reflection.

Table 2. Antitumor efficacy

Response	Full analysis set (n = 46)
CR	1 (2.2)
PR	26 (56.5)
SD	14 (30.4)
PD	2 (4.3)
NE	3 (6.5)
Overall response rate (CR + PR)	27 (58.7)
95% CI	43.9–73.5*

Figures in parentheses are percentages. NE = Not evaluable.
* One-sided p = 0.0008 (exact method with the null RR = 40%).

Toxicity and Tolerability

The 4 cycles of FOLFOX6 and the 4 cycles of FOLFIRI could each be prescribed alternatively, although there were some treatment delays because of adverse reactions. In the shortest case, only 1 cycle was completed because



Fig. 1. Progression-free survival.



Fig. 2. Overall survival.

Table 3. Treatment-related adverse events

	All grades	G3	G4
Anorexia	32 (68.10)	4 (8.50)	0
Fatigue	27 (57.40)	2 (4.30)	0
Nausea	27 (57.40)	1 (2.10)	1 (2.10)
Mucositis	19 (40.40)	0	0
Constipation	17 (36.20)	0	0
Neurotoxicity (CTCAE)	17 (36.20)	0	0
Diarrhea	15 (31.90)	1 (2.10)	0
Alopecia	13 (27.70)	0	0
Vomiting	13 (27.70)	0	1 (2.10)
Fever	8 (17.00)	0	1 (2.10)
Hand-foot syndrome	6 (12.80)	0	0
Allergic reaction	4 (8.50)	0	0
Chromatosis	2 (4.30)	0	0
Febrile neutropenia	2 (4.30)	2 (4.30)	0
Insomnia	2 (4.30)	0	0
Pneumonia	2 (4.30)	1	0
Weight loss	2 (4.30)	0	0
Epistaxis	1 (2.10)	0	0
Gastrointestinal bleeding	1 (2.10)	0	0
Anemia	42 (89.40)	2 (4.30)	0
Neutropenia	41 (87.20)	17 (36.20)	9 (19.10)
AST elevated	39 (83.00)	3 (6.40)	0
Thrombocytopenia	35 (74.50)	2 (4.30)	0
ALT elevated	24 (51.10)	1 (2.10)	1 (2.10)
Total bilirubin elevated	9 (19.10)	0	0

Figures in parentheses are percentages.

of allergic reactions, whereas 47 cycles were completed in the longest case. The adverse events are shown in table 3. Among the 47 patients evaluated for toxicity, the most common grade 3–4 adverse events were leukopenia (26%), neutropenia (55%), anemia (4%), diarrhea (2%), febrile neutropenia (4%), nausea (4%), and vomiting (2%). No grade 3–4 neurotoxicity, which is a dose-limiting toxicity of oxaliplatin, was reported; only 1 case of grade 3–4 diarrhea was reported. Grade 3–4 hypersensitivity reactions were not reported. Figure 3 illustrates the occurrence of neurotoxicity for each patient in each cycle. Neurotoxicity occurred primarily during the FOLFOX cycles, although some of the neurotoxicity subsided during the FOLFIRI cycles.

Discussion

Among patients with unresectable colorectal cancers, the duration of survival has increased in the past decade. This improvement resulted primarily from the introduction of oxaliplatin or irinotecan into 5-FU-based regimens; additionally, molecular targeting agents have played a role in extending patient survival [1–5]. It is known that patient outcome is significantly improved with exposure to all active drugs in the course of disease treatment [1, 2]. Thus, the sequential administration of FOLFOX and FOLFIRI in any order with molecular targeting agents is the standard treatment for unresectable colorectal cancer [4, 5]. However, approximately 20–30%



Fig. 3. Occurrence of neurotoxicity (CTCAE) in each cycle for all 47 patients. White squares indicate no toxicity; gray squares indicate grade 1 neurotoxicity; black squares indicate grade 2 neurotoxicity.

of patients exhibit PD after first-line therapy; hence, they do not receive further chemotherapy [6, 7]. Furthermore, an important limitation of this strategy is frequent grade 3 sensory neuropathy, which occurred in approximately one third of the patients initially treated using FOLFOX [15, 16]. This neuropathy forced many patients to stop oxaliplatin-containing treatment before tumor progression [1].

Three strategies have been proposed to avoid these toxicities and increase the rate of exposure to all active drugs. First, all 3 key drugs are administered during first-line therapy, as with the FOLFOXIRI regimen [8, 9, 12]. It is reported that combinations including irinotecan and oxaliplatin with 5-FU (FOLFOXIRI) are feasible. The principal benefit of the FOLFOXIRI regimen is its high RR; further, high liver resection rates have been reported. However, the toxicity of these drugs when given in combination results in dose reductions for each of the drugs [8, 10, 11].

The second strategy involves stop-and-go regimens such as the OPTIMOX series that include oxaliplatin-free intervals to reduce grade 3 sensory neuropathy [16]. This stop-and-go regimen avoided the problem of oxaliplatin-induced neurotoxicity by using a dose-intense FOLFOX7 regimen for a defined period, stopping the therapy before severe neurotoxicity developed, and later reintroducing the same regimen. This regimen was extremely useful for reducing the neurotoxicity of oxaliplatin; however, response and survival were not improved.

The third method involves alternating regimens such as 4 courses of FOLFOX and 4 courses of FOLFIRI, as investigated in this trial. To improve response and survival, other alternating regimens have been examined. Alternating oxaliplatin and irinotecan in association with the De Gramont regimen has been used in first- and second-line chemotherapy for metastatic colorectal cancer [17]. Seventy-nine patients with previously untreated, unresectable colorectal cancer were included in a study of this regimen as a first-line treatment. Treatment consisted of 5-FU/leucovorin plus oxaliplatin alternated biweekly with the same 5-FU/leucovorin regimen plus irinotecan. Treatment was maintained until tumor progression or unacceptable toxicity was noted. Grade 1 or 2 neurotoxicity was observed in 59% of cases, but no grade 3 and 4 neurotoxicity was observed. An objective RR of 54% was attained. The median time to progression and OS was 13

and 18 months, respectively. In another phase II study, GERCOR utilized an alternating regimen of 4 cycles of FOLFOX6 and 4 cycles of FOLFIRI (FIREFOX) as a second-line therapy in 39 patients with 5-FU-resistant unresectable colorectal cancer [18]. Eighteen patients had an objective response (46.1%). The median PFS and OS were 8.8 and 18.7 months, respectively. Only 2 patients (5.1%) exhibited grade 3 oxaliplatin-induced neuropathy. Another group evaluated an alternating XELFOX and XELFIRI regimen [19]. Treatment consisted of 2 consecutive days of 200 mg/m^2 leucovorin, 400 mg/m^2 5-FU and 2,000 mg/m^2 capecitabine in 1 cycle and the addition of 50 mg/m^2 oxaliplatin for 2 days before the combination treatment in the subsequent cycle.

To our knowledge, this study is the first to examine the efficacy and safety of an alternating regimen of 4 courses of FOLFOX6 followed by 4 courses of FOLFIRI in patients with non-pretreated metastatic colorectal cancer. The objective RR of 58.5% is better than that of the FOLFOX or FOLFIRI chemotherapy regimens without molecular targeting agents and is close to that of FOLFOXIRI chemotherapy [9]. This regimen might be a substitute for FOLFOXIRI which has a high rate of conversion to surgery. In our study, 9 (19.6%) patients were converted to surgery including liver resection. In addition, this strategy was implemented to increase the efficacy of treatment and extend survival. The median PFS and OS were 10.3 and 28.4 months, respectively. PFS for first-line FOLFOX6 or FOLFIRI treatment without molecular targeted agents was 8–10 months [1], and PFS increased to 10–14 months when second-line treatment was also administered. Therefore, PFS in this study was not long, although OS was extended. This survival may be partly influenced by the therapy that followed the treatment administered in the study. In this phase II study, because molecular targeted agents were not included in the protocol treatment, FOLFOX6 and FOLFIRI with molecular targeted agents were chosen as the second-line treatment. At present, oral fluoropyrimidine with molecular target agents were considered as a choice as a second therapy and the third therapy. Although survival was not a primary endpoint, the remarkably long OS associated with the FIREFOX regimen is noteworthy. Furthermore, the most remarkable result in this study was the low level of neurotoxicity. In particular, no grade 3–4 peripheral neurotoxicity was observed. Only 6 patients experienced grade 2 neurotoxicity. Figure 3 shows the occurrence of neurotoxicity in all patients. Neurotoxicity improved during the FOLFIRI cycles. This tendency was similar to that observed with the OPTIMOX regimen. However, the OPTIMOX regimen does not have a chemotherapy-free interval; therefore, PFS can be maintained well. In this phase II trial, only 6 (12.7%) patients did not receive FOLFIRI because of disease progression or patient refusal. The high usage rate for the 3 active drugs is advantageous for this regimen because 20–30% of patients cannot receive second-line chemotherapy because of disease progression. Therefore, this low level of neurotoxicity may have greatly contributed to the long PFS and OS in this study.

Our findings suggest that the alternating administration of 4 cycles of FOLFOX6 and 4 cycles of FOLFIRI (FIREFOX) is effective and well tolerated as a first-line treatment for metastatic colorectal cancer. A favorable toxicity profile and prolonged time to progression were observed. Based on this study, we recently conducted and finished another phase II study of 4 alternating cycles of FOLFOX6 and FOLFIRI with bevacizumab.

Disclosure Statement

Yoshihiko Maehara is partly supported by research funding from Yakult Honsha Co., Ltd.

References

1 Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229–237.

2 Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, Schulz J, Richards D, Soufi-Mahjoubi R, Wang B, Barrueco J: Randomized, controlled trial of irinotecan plus infusional bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007;25:4779–4786.

3 Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M, Amado RG: Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25:1658–1664.

4 Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pinter T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408–1417.

5 Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335–2342.
6 Grothey A, Sargent D, Goldberg RM, Schmoll HJ: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004;22:1209–1214.
7 Grothey A, Sargent D: Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol 2005;23:9441–9442.
8 Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, Crino L, Benedetti G, Evangelista W, Fanchini L, Cortesi E, Picone V, Vitello S, Chiara S, Granetto C, Porcile G, Fioretto L, Orlandini C, Andreuccetti M, Masi G: Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007;25:1670–1676.
9 Souglakos J, Androulakis N, Syrigos K, Polyzos A, Ziras N, Athanasiadis A, Kakolyris S, Tsousis S, Kouroussis C, Vamvakas L, Kalykaki A, Samonis G, Mavroudis D, Georgoulias V: FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer 2006;94:798–805.
10 Masi G, Loupakis F, Salvatore L, Fornaro L, Cremolini C, Cupini S, Ciarlo A, Del Monte F, Cortesi E, Amoroso D, Granetto C, Fontanini G, Sensi E, Lupi C, Andreuccetti M, Falcone A: Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol 2010;11:845–852.
11 Montagnani F, Chiriatti A, Turrisi G, Francini G, Fiorentini G: A systematic review of FOLFOXIRI chemotherapy for the first-line treatment of metastatic colorectal cancer: improved efficacy at the cost of increased toxicity. Colorectal Dis 2011;13:846–852.
12 Masi G, Allegrini G, Cupini S, Marcucci L, Cerri E, Brunetti I, Fontana E, Ricci S, Andreuccetti M, Falcone A: First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule. Ann Oncol 2004;15:1766–1772.
13 Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P: CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13:176–181.
14 Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205–216.
15 Vaidyanathan G, Groman A, Wilding G, Fakih MG: Stop and go FOLFOX plus bevacizumab chemotherapy in the first-line treatment of metastatic colorectal cancer. Oncology 2010;79:67–71.
16 Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, Mineur L, Carola E, Etienne PL, Rivera F, Chirivella I, Perez-Staub N, Louvet C, Andre T, Tabah-Fisch I, de Gramont A: OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer – a GERCOR study. J Clin Oncol 2006;24:394–400.
17 Aparicio J, Fernandez-Martos C, Vincent JM, Maestu I, Llorca C, Busquier I, Campos JM, Perez-Enguix D, Balcells M: FOLFOX alternated with FOLFIRI as first-line chemotherapy for metastatic colorectal cancer. Clin Colorectal Cancer 2005;5:263–267.
18 Hebbar M, Tournigand C, Lledo G, Mabro M, Andre T, Louvet C, Aparicio T, Flesch M, Varette C, de Gramont A, Oncology Multidisciplinary Research G: Phase II trial alternating FOLFOX-6 and FOLFIRI regimens in second-line therapy of patients with metastatic colorectal cancer (FIREFOX study). Cancer Invest 2006;24:154–159.
19 Recchia F, Candeloro G, Necozione S, Bratta M, Bisegna R, Rea S: Alternating XELFOX and XELFIRI in patients with metastatic colorectal cancer. Am J Clin Oncol 2008;31:323–328.

Springer

Dear Author

Here are the proofs of your article.

- You can submit your corrections **online,** via **e-mail** or by **fax**.
- For **online** submission please insert your corrections in the online correction form. Always indicate the line number to which the correction refers.
- You can also insert your corrections in the proof PDF and **email** the annotated PDF.
- For **fax** submission, please ensure that your corrections are clearly legible. Use a fine black pen and write the correction in the margin, not too close to the edge of the page.
- Remember to note the **journal title**, **article number**, and **your name** when sending your response via e-mail or fax.
- **Check** the metadata sheet to make sure that the header information, especially author names and the corresponding affiliations are correctly shown.
- **Check** the questions that may have arisen during copy editing and insert your answers/corrections.
- **Check** that the text is complete and that all figures, tables and their legends are included. Also check the accuracy of special characters, equations, and electronic supplementary material if applicable. If necessary refer to the *Edited manuscript*.
- The publication of inaccurate data such as dosages and units can have serious consequences. Please take particular care that all such details are correct.
- Please **do not** make changes that involve only matters of style. We have generally introduced forms that follow the journal's style.
- Substantial changes in content, e.g., new results, corrected values, title and authorship are not allowed without the approval of the responsible editor. In such a case, please contact the Editorial Office and return his/her consent together with the proof.
- If we do not receive your corrections **within 48 hours**, we will send you a reminder.
- Your article will be published **Online First** approximately one week after receipt of your corrected proofs. This is the **official first publication** citable with the DOI. **Further changes are, therefore, not possible.**
- The **printed version** will follow in a forthcoming issue.

Please note

After online publication, subscribers (personal/institutional) to this journal will have access to the complete article via the DOI using the URL:

`http://dx.doi.org/10.1007/s12029-012-9471-5`

If you would like to know when your article has been published online, take advantage of our free alert service. For registration and further information, go to: http://www.springerlink.com.

Due to the electronic nature of the procedure, the manuscript and the original figures will only be returned to you on special request. When you return your corrections, please inform us, if you would like to have these documents returned.

Metadata of the article that will be visualized in OnlineFirst

1	Article Title	**Treatment of Patients with Stage IV Gastric Cancer**	
2	Article Sub- Title		
3	Article Copyright - Year	**Springer Science+Business Media New York 2012 (This will be the copyright line in the final PDF)**	
4	Journal Name	Journal of Gastrointestinal Cancer	
5	Corresponding Author	Family Name	**Ikeguchi**
6		Particle	
7		Given Name	**Masahide**
8		Suffix	
9		Organization	Tottori University
10		Division	Department of Surgery, Division of Surgical Oncology, Faculty of Medicine
11		Address	36-1 Nishi-cho, Yonago 683-8504, Japan
12		e-mail	masaike@med.tottori-u.ac.jp
13	Author	Family Name	**Kader**
14		Particle	
15		Given Name	**Abdul**
16		Suffix	
17		Organization	Tottori University
18		Division	Department of Surgery, Division of Surgical Oncology, Faculty of Medicine
19		Address	36-1 Nishi-cho, Yonago 683-8504, Japan
20		e-mail	
21	Author	Family Name	**Takaya**
22		Particle	
23		Given Name	**Seigo**
24		Suffix	
25		Organization	Tottori University
26		Division	Department of Surgery, Division of Surgical Oncology, Faculty of Medicine
27		Address	36-1 Nishi-cho, Yonago 683-8504, Japan
28		e-mail	
29	Author	Family Name	**Fukumoto**

30		Particle	
31		Given Name	**Youji**
32		Suffix	
33		Organization	Tottori University
34		Division	Department of Surgery, Division of Surgical Oncology, Faculty of Medicine
35		Address	36-1 Nishi-cho, Yonago 683-8504, Japan
36		e-mail	
37		Family Name	**Osaki**
38		Particle	
39		Given Name	**Tomohiro**
40		Suffix	
41	Author	Organization	Tottori University
42		Division	Department of Surgery, Division of Surgical Oncology, Faculty of Medicine
43		Address	36-1 Nishi-cho, Yonago 683-8504, Japan
44		e-mail	
45		Family Name	**Saito**
46		Particle	
47		Given Name	**Hiroaki**
48		Suffix	
49	Author	Organization	Tottori University
50		Division	Department of Surgery, Division of Surgical Oncology, Faculty of Medicine
51		Address	36-1 Nishi-cho, Yonago 683-8504, Japan
52		e-mail	
53		Family Name	**Tatebe**
54		Particle	
55		Given Name	**Shigeru**
56		Suffix	
57	Author	Organization	Tottori University
58		Division	Department of Surgery, Division of Surgical Oncology, Faculty of Medicine
59		Address	36-1 Nishi-cho, Yonago 683-8504, Japan
60		e-mail	
61		Family Name	**Wakatsuki**
62	Author	Particle	
63		Given Name	**Toshiro**

64		Suffix	
65		Organization	Tottori University
66		Division	Department of Surgery, Division of Surgical Oncology, Faculty of Medicine
67		Address	36-1 Nishi-cho, Yonago 683-8504, Japan
68		e-mail	
69		Received	
70	Schedule	Revised	
71		Accepted	
72	Abstract	**Purpose:** Treatment of patients with stage IV gastric cancer is controversial. This study was retrospectively designed to elucidate the best treatment for these patients. **Methods:** Between 2003 and 2010, a total of 558 patients with gastric cancer were treated at the Department of Surgery, Tottori University Hospital, 96 (17.2 %) of whom were diagnosed with stage IV. Among 96, 54 underwent palliative gastrectomy while 42 underwent chemotherapy, exploratory laparotomy, or gastrojejunostomy for unresectable cases. Surgical morbidity, mortality, and patient survival were analyzed with respect to several factors. **Results:** Among resected cases, high age, R2 operation, and neoadjuvant chemotherapy did not increase the occurrence of postoperative complications. Patient age, R1 operation, and sufficient chemotherapy were indicated as better prognostic factors for resected stage IV gastric cancers. Even after R2 operation, continuous chemotherapy with changing regimens prolonged R2 resected patients' survival to 25 months (mean). In unresectable cases, bypass operation did not affect patients' survival. But, chemotherapy with changing regimens prolonged the survival of unresectable cases. **Conclusions:** Adequate management can resolve surgery-related morbidity, and continuous chemotherapy may be one of the most important prognostic factors in stage IV gastric cancer.	
73	Keywords separated by ' - '	Gastric cancer - Gastrectomy - Chemotherapy - Prognosis - Resectability	
74	Foot note information		

JrnlID 12029_ArtID 9471_Proof# 1 - 11/12/2012

J Gastrointest Canc
DOI 10.1007/s12029-012-9471-5

ORIGINAL RESEARCH

Treatment of Patients with Stage IV Gastric Cancer

Masahide Ikeguchi · Abdul Kader · Seigo Takaya · Youji Fukumoto · Tomohiro Osaki · Hiroaki Saito · Shigeru Tatebe · Toshiro Wakatsuki

Abstract

Purpose Treatment of patients with stage IV gastric cancer is controversial. This study was retrospectively designed to elucidate the best treatment for these patients.

Methods Between 2003 and 2010, a total of 558 patients with gastric cancer were treated at the Department of Surgery, Tottori University Hospital, 96 (17.2 %) of whom were diagnosed with stage IV. Among 96, 54 underwent palliative gastrectomy while 42 underwent chemotherapy, exploratory laparotomy, or gastrojejunostomy for unresectable cases. Surgical morbidity, mortality, and patient survival were analyzed with respect to several factors.

Results Among resected cases, high age, R2 operation, and neoadjuvant chemotherapy did not increase the occurrence of postoperative complications. Patient age, R1 operation, and sufficient chemotherapy were indicated as better prognostic factors for resected stage IV gastric cancers. Even after R2 operation, continuous chemotherapy with changing regimens prolonged R2 resected patients' survival to 25 months (mean). In unresectable cases, bypass operation did not affect patients' survival. But, chemotherapy with changing regimens prolonged the survival of unresectable cases.

Conclusions Adequate management can resolve surgery-related morbidity, and continuous chemotherapy may be one of the most important prognostic factors in stage IV gastric cancer.

Keywords Gastric cancer · Gastrectomy · Chemotherapy · Prognosis · Resectability

M. Ikeguchi (✉) · A. Kader · S. Takaya · Y. Fukumoto · T. Osaki · H. Saito · S. Tatebe · T. Wakatsuki
Department of Surgery, Division of Surgical Oncology, Faculty of Medicine, Tottori University, 36-1 Nishi-cho, Yonago 683-8504, Japan
e-mail: masaike@med.tottori-u.ac.jp

Introduction

Gastric cancer is a common malignancy of the gastrointestinal tract. Surgical resection plays the most important role in achieving curability [1, 2]. However, many patients have incurable advanced-stage gastric cancer. For these patients, the aim of palliative resection is relief of symptoms such as obstruction, tumor bleeding, or perforation. Medina-Franco et al. reported that surgical resection for stage IV gastric cancer can be performed with low operative mortality and acceptable morbidity rates, and it provides patients with good symptomatic relief [3]. However, the survival benefit of palliative gastrectomy or reduction surgery for advanced-stage gastric cancer is still debatable. According to the 2009 annual report of the Japanese Gastric Cancer Association (JGCA), which was based on the JGCA classification 13th edition [4], the 5-year survival rate of unresected cases was 1.5 %, but increased to 14.9 % in resected stage IV cases [5]. In the JGCA classification 13th edition, many cases with resected stage IV included many R0 operations (no residual tumor). Therefore, the standard of the 13th edition is not suitable for investigation of palliative or reduction surgery for stage IV stomach cancer.

The aim of this study was to analyze the survival benefits of palliative reduction gastrectomy or surgical intervention (bypass operation) in patients with stage IV gastric cancer diagnosed by the new JGCA classification 14th edition [6, 7].

Methods

Between 2003 and 2010, a total of 558 patients were diagnosed with gastric cancer and treated at the Department of Surgery, Tottori University Hospital. According the new JGCA classification 14th edition (third English edition) [6], 96 patients (17.2 %) were diagnosed with stage IV cancer. Of

these 96 patients, 54 (56.3 %) underwent palliative gastrectomy. However, 42 patients (43.8 %) did not undergo resection for advanced gastric cancer because of local invasion of tumors. Of these patients, one underwent exploratory laparotomy only and nine underwent gastrojejunostomy as a bypass procedure for gastric outlet obstruction. R1 and R2 resection were defined as resection of microscopic and macroscopic residual tumors, respectively [6]. Of the 54 patients who underwent palliative gastrectomy, total gastrectomy was performed in 40 patients and partial gastrectomy was performed in 14 patients. R1 and R2 operations were performed in 22 and 32 patients, respectively. In addition, 24 patients (44.4 %) underwent neoadjuvant chemotherapy. The neoadjuvant chemotherapy regimens were S-1+cisplatin (n=18) and S-1+docetaxel (n=6). All surgical specimens were examined by experienced pathologists. The results of surgical treatment, including surgical morbidity, mortality, and patient survival, were evaluated. Death during the hospital stay or within 30 days after the operation was defined as hospital mortality.

Best supportive care with no chemotherapy was decided for nine patients. Because, some patients were in poor performance status, were high aged, or some patients did not desire anticancer drug medical treatment. Chemotherapy was performed for remaining 87 patients. One chemotherapeutic regimen was performed in 21 patients, two chemotherapeutic regimens were performed for 36 patients, and three or more chemotherapeutic regimens were performed in 30 patients.

Clinicopathological differences were compared with χ^2 tests. Survival curves were created using the Kaplan–Meier method, and differences between the survival curves were analyzed by the log-rank test. Multivariate analysis was performed using a multiple linear regression analysis and stepwise procedure. Univariate and multivariate analyses of prognosis were performed using the Cox proportional hazards model. A P value of <0.05 was considered statistically significant.

Results

The 2-year survival rate of the 96 patients with stage IV gastric cancer was 17.3 %. The 2-year survival rate of the 54 patients who underwent palliative gastrectomy (23.2 %) was significantly better than that of the 42 patients with unresectable cancer (6.6 %, P=0.004).

Postoperative complications occurred in ten (18.5 %) patients (pancreatic juice leakage, five; anastomotic leakage, two; anastomotic stenosis, one; intra-abdominal bleeding, one; and cerebral infarction, one). One patient died of cerebral infarction (operative mortality, 1.9 %) within 30 days after surgery during the hospital stay. The occurrence of postoperative complications did not correlate with patient age (≥75 years, 1/12, 8.3 % and <75 years, 9/42, 21.4 %; P=0.303), with the presence or absence of neoadjuvant chemotherapy (12.5 and 23.3 %, respectively; P=0.309), with the degree of residual tumors (R1 or R2 operation, 22.7 and 15.6 %, respectively; P=0.509), or with the operation method (total or partial gastrectomy, 20 and 14.3 %, respectively; P=0.636).

The clinical factors affecting the survival of patients with stage IV gastric cancer who underwent gastrectomy were investigated. In the univariate survival analysis, the 2-year survival rate of 12 older patients (≥75 years, 0 %) was worse than that of 42 younger patients (<75 years, 30.8 %; P=0.005). In addition, the 2-year survival rate of 19 patients who underwent three or more chemotherapeutic regimens (41.4 %) was better than that of 35 patients who underwent fewer than three chemotherapeutic regimens (17 %, P=0.012). R1 operations (n=22; 2-year survival rate, 40.9 %) showed better survival than R2 operations (n=32; 2-year survival rate, 14.1 %), but the difference was not statistically significant (P=0.071). In addition, we found that continuing chemotherapy while changing regimens was important to improve the prognosis of patients with stage IV R2 resected gastric cancer. Three or more chemotherapeutic regimens were performed for 12 of 32 patients who underwent R2 operations, and the mean survival time (MST) of these 12 patients was 25 months (Table 1). Operation method, postoperative complications, and neoadjuvant chemotherapy did not affect patient survival. The results of the multivariate survival analysis are shown in Table 2. Patient age, R1 operation, and sufficient chemotherapy were indicated as important prognostic factors for resected stage IV gastric cancers.

Nine of 42 patients with unresectable stage IV gastric cancer underwent a bypass operation (gastrojejunostomy). We investigated the prognostic factors for these unresected cases. The survival curves of patients were compared with respect to five parameters (Table 3). In univariate and multivariate analyses, the bypass operation did not improve the survival of the patients and only sufficient chemotherapy with changing regimens was detected as a prognostic factor for unresectable stage IV gastric cancers.

Table 1 Mean survival time of 54 resected cases according to degree of residual tumors (R1/R2) and number of chemotherapeutic regimens; ≥3/<3chemotherapeutic regimens

Degree of residual tumors	Number of chemotherapeutic regimens	Number of patients	Mean survival time (months)
R1	<3	15	33.3
R1	≥3	7	42.9
R2	<3	20	5
R2	≥3	12	25

t2.1 **Table 2** Analysis of positive prognostic factors in 54 patients who underwent gastrectomy by the Cox proportional hazards model

	95 % CI	Hazard ratio	*P*
Age; young (<75)/high aged (≥75)	1.159–5.485	2.521	0.019
Gastrectomy; partial/total	0.32–1.539	0.702	0.377
Degree of residual tumors; R1/R2	1.284–5.236	2.591	0.008
Postoperative complication; no/yes	0.728–3.463	1.587	0.246
Neoadjuvant chemotherapy; yes/no	0.844–3.273	1.662	0.142
Number of chemotherapeutic regimens; <3/≥3	1.445–5.863	2.910	0.003

Discussion

Palliative gastrectomy was performed in 56 % of patients with stage IV gastric cancer in our series. Oñate-Ocaña et al. [8] reported that palliative gastrectomy was performed in 33 % of patients with stage IV cancer and found that surgical morbidity was higher in R2 operations (32.4 %) than in R1 operations (19 %). They concluded that the low immunonutritional status of the R2 resection group was the main factor contributing to the high morbidity and mortality rates in this group. In addition, they reported that the rate of morbidity after total gastrectomy was higher than that after distal gastrectomy. Hartgrink et al. [2] reported that patients >70 years of age had a higher mortality rate ($P<0.001$) after palliative gastrectomy. However, in our cohort, postoperative complications occurred in 18.5 % of patients and did not correlate with patient age, with R1 or R2 operations, or with operation methods. Although our cohort was very small, our results may indicate that careful pre- and postoperative nutritional management and a precise operation technique may allow for safe performance of palliative gastrectomy even in elderly patients. Thus, advanced patient age is not a contraindication for surgical treatment [3].

The prognosis of stage IV gastric cancer is poor. Many reports have indicated that palliative gastrectomy improves the prognosis of patients with stage IV cancer [5, 9, 10]. However, many of the unresectable cases were more advanced. Thus, the prognostic factors of patients with stage IV gastric cancer should be discussed separately in resectable and unresectable cases. Sougioultzis et al. [9] reported that palliative gastrectomy and combination chemotherapy appeared to be associated with improved survival. However, the effectiveness of neoadjuvant chemotherapy is controversial. Hartgrink et al. [11] stated that neoadjuvant chemotherapy did not increase postoperative morbidity, but it did not improve the survival of patients with advanced gastric cancer. In addition, our results demonstrated that neoadjuvant chemotherapy did not prolong the survival of patients with resected stage IV gastric cancer.

It is difficult to determine whether chemotherapy with changing regimens is a cause or an effect of better survival of patients with stage IV gastric cancer. However, we found that postoperative chemotherapy with changing regimens was an important positive prognostic factor for patients with resected stage IV gastric cancer, even after R2 operation. There was a trend toward better overall survival after adjuvant chemotherapy. Several recent studies have shown that chemotherapy provides a slight benefit with respect to survival in patients with late-stage gastric cancer after palliative gastrectomy [12, 13]. Moreover, in the present study, chemotherapy with changing regimens was the most important prognostic factor for patients with unresectable gastric cancer.

If a patient has obstructive symptoms, bypass surgery may provide symptom relief. However, in our series, bypass surgery did not improve the patients' prognosis. The median overall survival was 10 months for both patients who did and did not undergo bypass surgery ($P=0.359$). Medina-Franco et al. [3] reported that if patients had symptoms such as bleeding, dysphagia, or gastric outlet obstruction, palliative resection provided symptom relief 85 % of the time while bypass surgery provided relief 60 % of the time. Surgical resection can provide better palliation of symptoms than can bypass surgery.

In conclusion, patients with noncurative gastric cancer had better survival when resection was performed. Palliative resection is not contraindicated in elderly patients with gastric cancer. Surgery-related morbidity can be resolved with adequate management. Even in patients after R2 operation or with unresectable cancer, chemotherapy with changing regimens may prolong survival.

t3.1 **Table 3** Prognostic factors of 42 patients with unresectable gastric cancer

	N	Mean survival time (months)	*P*
Age; young (<75)/high aged (≥75)	30/12	10/4	0.463
Ascites; no/yes	33/9	10/8	0.753
Bypass operation; no/yes	33/9	10/10	0.359
Number of chemotherapeutic regimens; <3/≥3	31/11	6/21	<0.001

Conflict of Interest All of the authors (Masahide Ikeguchi, Abdul Kader, Seigo Takaya, Youji Fukumoto, Tomohiro Osaki, Hiroaki Saito, Shigeru Tatebe, and Toshiro Wakatsuki) declare that they have no conflict of interest.

References

1. Wu CW, Hsiung CA, Lo SS, Hsieh MC, Chen JH, Li AF, et al. Nodal dissection for patients with gastric cancer: a randomized controlled trial. Lancet Oncol. 2006;7:309–15.
2. Hartgrink HH, van de Velde CJ, Putter H, Bonenkamp JJ, Klein Kranenbarg E, Songun I, et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol. 2004;22:2069–77.
3. Medina-Franco H, Contreras-Saldívar A, Ramos-De La Medina A, Palacios-Sanchez P, Cortés-González R, Alvarez-Tostado Ugarte J. Surgery for stage IV gastric cancer. Am J Surg. 2004;187:543–6.
4. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma—2nd English edition. Gastric Cancer. 1998;1:10–24.
5. Nashimoto A, Akazawa K, Isobe Y, Miyashiro I, Katai H, Kodera Y, et al. Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry. Gastric Cancer. 2012. doi:10.1007/s10120-012-0163-4.
6. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14:101–12.
7. Association JGC. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer. 2010;14:113–23.
8. Oñate-Ocaña LF, Méndez-Cruz G, Hwrnández-Ramos R, Becker M, Carrillo JF, Herrera-Goepfert R, et al. Experience of surgical morbidity after palliative surgery in patients with gastric carcinoma. Gastric Cancer. 2007;10:215–20.
9. Sougioultzis S, Syrios J, Xynos ID, Bovaretos N, Kosmas C, Sarantonis J, et al. Palliative gastrectomy and other factors affecting overall survival in stage IV gastric adenocarcinoma patients receiving chemotherapy: a retrospective analysis. Eur J Surg Oncol. 2011;37:312–8.
10. Hioki M, Gotohda N, Konishi M, Nakagohri T, Takahashi S, Kinoshita T. Predictive factors improving survival after gastrectomy in gastric cancer patients with peritoneal carcinomatosis. World J Surg. 2010;34:555–62.
11. Hartgrink HH, van de Velde CJ, Putter H, Songun I, Tesselaar ME, Kranenbarg EK, et al. Cooperating investigators of the dutch gastric cancer group. Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the dutch randomised FAMTX trial. Eur J Surg Oncol. 2004;30:643–9.
12. Okuyama T, Korenaga D, Koushi K, Itoh S, Kawanaka H, Ikeda Y, et al. The prognostic significance of chemotherapy for stage IV gastric cancer patients: a single-institution experience. Surg Today. 2011;41:935–40.
13. Ishigami S, Natsugoe S, Nakajo A, Matsumoto M, Uenosono Y, Arigami T, et al. Salvage gastrectomy following a combination of biweekly paclitaxel and S-1 for stage IV gastric cancer. J Gastrointest Surg. 2008;12:1370–5.

AUTHOR QUERY

AUTHOR PLEASE ANSWER QUERY.

No Query.

Usefulness of palliative prognostic score in the treatment of patients with non-resectable gastric cancer

MASAHIDE IKEGUCHI, ABDUL KADER, MIWA YOSHIMOTO, SEIGO TAKAYA, JOJI WATANABE, YOUJI FUKUMOTO, TOMOHIRO OSAKI, HIROAKI SAITO, SHIGERU TATEBE and TOSHIRO WAKATSUKI

Department of Surgery, Division of Surgical Oncology, Faculty of Medicine, Tottori University, Yonago 683-8504, Japan

Received July 11, 2012; Accepted December 11, 2012

DOI: 10.3892/mco.2013.66

Abstract. The aim of this study was to evaluate the clinical usefulness of the palliative prognostic (PaP) score in patients with non-resectable advanced gastric cancer. The PaP score was calculated prior to each course of chemotherapy in 44 consecutive patients with non-resectable advanced gastric cancer between 2003 and 2010 at the Tottori University Hospital, Yonago, Japan. The prognosis was evaluated according to the PaP score and the different chemotherapeutic agents. The median survival time (MST) was 10 months. The PaP score classified the heterogeneous patient sample into three isoprognostic groups with regard to the possibility of a 1-month survival period, with 28 patients in group A (>70% chance), 12 in group B (30-70% chance) and 4 in group C (<30% chance). The MST of the three groups was 11, 3 and 1 months for group A, B and C, respectively. In group A, chemotherapeutic regimens did not affect patient survival, although the docetaxel regimen prolonged survival of patients in group B. In conclusion, the PaP score may be useful in selecting the best chemotherapeutic regimen in patients with non-resectable gastric cancer.

Introduction

Outcomes are extremely poor in patients with non-resectable gastric cancer, with a median survival period ranging from 3 to 5 months, even with the best supportive care (1,2). S-1 is an oral anticancer drug that combines tegafur, a prodrug of fluorouracil, with 5-chloro-2,4-dihydropyrimidine (CDHP) and potassium oxonate at a molar ratio of 1:0.4:1 (Taiho Pharmaceutical Co., Ltd., Tokyo, Japan) (3). In a phase II study of S-1, an ~40% response rate was noted in patients with advanced gastric cancer (4,5). Thus, S-1 chemotherapy has been widely used as a basic treatment for patients with non-resectable gastric cancer. Findings from the SPIRIT trial identified S-1 plus cisplatin as a standard first-line treatment (6) and recommended its use in patients with an expected survival period of at least 3 months. However, due to the severe side effects, the S-1 plus cisplatin regimen [S-1: 40-60 mg/m^2; in a 5-week cycle (3 weeks on and 2 weeks off), in combination with 60 mg/m^2 cisplatin on day 8] was difficult to continue in patients with poor Eastern Cooperative Oncology Group Performance Status (ECOG PS). Additionally, a number of patients suffered from reduced quality of life (QOL) while undergoing this medical treatment (7). However, Casaretto *et al* (8) reported that chemotherapy increased the 1-year survival rate, provided a longer symptom-free period and improved the QOL of patients with non-resectable advanced gastric cancer. Clinically, it is important to select chemotherapeutic regimens that are most appropriate for the patient's condition.

The objective indicators determining suitable chemotherapy regimens for patients with non-resectable gastric cancer have been studied. The standard prognostic indicators in oncology, such as tumor size, grade and stage, or molecular biology, are less relevant in patients with advanced cancer. The palliative prognostic (PaP) score was developed in the 1990s, as a result of a series of prospective trials aimed to identify clinical and biologic factors associated with the prognosis of advanced cancer patients referred to hospice and to merge them into a prognostic index (9). The survival of patients with non-resectable or recurrent cancers can be estimated using the PaP score even during chemotherapy (10).

In this study, the usefulness of the PaP score in determining the first-line chemotherapy for patients with non-resectable gastric cancer was examined retrospectively.

Materials and methods

Patients. Between 2003 and 2010, 558 patients with gastric cancer were treated at the Tottori University Hospital, Yonago, Japan. Forty-four patients (7.9%) were diagnosed as non-resectable. Details of these 44 patients are shown in Table I. Patients were followed up at the hospital until March 2012. During this period, gastrectomy was performed on 3 patients (bleeding, 2 patients; perforation, 1 patient). All participants provided informed consent and the study design was approved by the Ethics Review Board of Tottori University.

Correspondence to: Dr Masahide Ikeguchi, Department of Surgery, Division of Surgical Oncology, Faculty of Medicine, Tottori University, 36-1 Nishi-cho, Yonago 683-8504, Japan
E-mail: masaike@med.tottori-u.ac.jp

Key words: docetaxel, palliative prognostic score, non-resectable gastric cancer

Table I. Patient data (n=44).

Variables	No.
Age (range, mean; years)	23-92, 66.5
Gender (male/female)	24/20
Ascites (yes/no)	10/34
ECOG PS (0/1/2)	14/18/12
Non-resectable parameters	
Locally advanced	6
Lymph node	12
Hematogenic metastasis	19
Peritoneal metastasis	20
Surgical intervention	
No	29
Probe-laparotomy	1
Bypass operation	11
Gastrectomy	3

ECOG PS, Eastern Cooperative Oncology Group performance status.

Table II. PaP score.

Item	Score
Symptoms (presence/absence)	
Anorexia	1.0/0.0
Dyspnea	1.5/0.0
Karnofsky performance status	
≥50	0.0
30-40	0.0
10-20	2.5
Clinical prediction of survival (weeks)	
>12	0.0
11-12	2.0
9-10	2.5
7-8	2.5
5-6	4.5
3-4	6.0
1-2	8.5
Total white blood cells (/mm^3)	
Normal (4,800-8,500)	0
High (8,501-11,000)	0.5
Very high (>11,000)	1.5
Lymphocyte percentage	
Normal (20.0-40.0)	0
Low (12.0-19.9)	1.0
Very low (0-11.9)	2.5
PaP score groups	
A	0-5.5
B	5.6-11.0
C	11.1-17.5

PaP, palliative prognostic.

Chemotherapy. First-line chemotherapy was received by 41 patients (S-1, 7; S-1 plus cisplatin, 17; S-1 plus docetaxel, 13; other chemotherapy, 4). Chemotherapy was terminated in the case of 3 patients with poor performance status (PS) and advanced age, who then received best supportive care (BSC).

PaP score. The PaP score has four criteria: two symptoms (anorexia and dyspnea), performance status measured by the Karnofsky performance score, white blood cells (WBC) abnormalities (high total WBC count and lymphopenia) and a physician's survival prediction measured in weeks (Table II). Validated cut-off points based on the total PaP score were established to classify the patients into three prognostic groups for survival at 30 days: group A (>70% probability of a 1-month survival period), 0 to 5.5 points; group B (30-70% probability of a 1-month survival period), 5.6 to 11 points; group C (<30% probability of a 1-month survival), 11.1-17.5 points (10,11) (Table II).

Statistical analysis. The terminology used in this study conforms to the Japanese Classification of Gastric Carcinoma, 3rd English edition (12). Statistical analysis was carried out using χ^2 tests. Overall survival was calculated from the time of enrolment to death. Median survival time (MST) was calculated using the Kaplan-Meier non-parametric test, while comparison between the different patient cohorts was performed using the log-rank test. $P<0.05$ was considered to indicate a statistically significant difference.

Results

Median survival time. The MST of the 44 patients was 10 months. Patients were divided into 3 subgroups, according to their PaP score. The MST of 28 patients in group A (11 months) was much better compared to the 12 patients in group B (3 months) or the 4 patients in group C (1 month, $P<0.0001$, Fig. 1). In the 40 patients in groups A and B, the correlation between prognosis and factors considered to affect the prognosis was analyzed (Table III). The presence or absence of ascites or bypass surgery did not affect patient survival.

Correlation between the PaP score and the first-line chemotherapy regimens. The correlation between the PaP score and the first-line chemotherapy regimens are shown in Table IV. The S-1 plus cisplatin regimen was commonly used as first-line chemotherapy in PaP group A. However, due to renal dysfunction, cisplatin was not used in a number of patients in group B, thus S-1 plus docetaxel or S-1 alone was selected in this group instead. In the 28 patients in group A, the MST using the cisplatin regimen (10 months, n=16) did not differ from the other regimens (11 months, n=12, $P=0.221$). Although the difference was not significant ($P=0.062$), in the 12 patients